Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 31.68 as of 2026-09-11T02:33:42.633Z.
Consensus retrieved: 2026-09-11T01:04:36.519Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-11T02:33:42.633Z.
Quote observation: 2026-09-10T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8237d54513fe590b1f0ccbf83172440dd636f2ed9cd2551f17e23848d9509eee
Forward PE Ratio (31.68) = Dated Quote Price ($84.51) / Consensus Forward EPS ($2.67)
FORWARD PE RATIO
31.68
SECTOR MEDIAN · HEALTHCARE
18.93
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+67.35%
vs the sector median at left
DexCom, Inc.
Market Cap
$31.89B
Forward PE Ratio
31.68
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| DexCom, Inc. (DXCM) | $31.89B | 31.68 |
| ResMed Inc. (RMD)vs › | $31.85B | 18.16 |
| Biogen Inc. (BIIB)vs › | $31.83B | 17.25 |
| Centene Corp. (CNC)vs › | $32.31B | 13.62 |
| Alcon Inc. (ALC)vs › | $32.46B | 19.05 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $33.12B | 37.09 |
| Zoetis Inc. (ZTS)vs › | $30.56B | 11.66 |
| Waters Corporation (WAT)vs › | $30.04B | 27.56 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.02B | 13.04 |
| Medline Inc. (MDLN)vs › | $27.39B | 21.70 |
Trailing P/E
33.4
reported TTM EPS
Forward P/E
31.7
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.67 implies +5.5% EPS growth vs the reported trailing $2.53.
At the dated quote price of $84.51, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.67 | $2.48 – $2.73 | 15 | 31.7x |
| 2027-12-31 | $3.12 | $2.87 – $3.33 | 16 | 27.1x |
| 2028-12-31 | $3.72 | $2.91 – $4.01 | 7 | 22.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
